ALIM News and Press, Alimera Sciences Inc. From 06/24/24

2024-06-24 17:00:04 ET Chase Knickerbocker from Craig-Hallum issued a price target of $5.50 for ALIM on 2024-06-24 15:58:00. The adjusted price target was set to $5.50. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $118.11 on volume of 457,565,587 shares Agrify Corporation (AGFY) rose 68.7% to $0.4251 on volume of 291,898,257 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 13.7% to $0.3662 on volume...

Alimera Sciences, Inc. (NASDAQ: ALIM) is one of today's top gainers. The company's shares have moved 75.56% on the day to $5.53. Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internation...

A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent...

2024-06-24 07:23:16 ET More on ANI Pharmaceuticals ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript ANI Pharmaceuticals Q1 2024 Earnings Preview Seeking Alpha’s Qua...

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue Adds two commercial assets ILUVIEN ® and YUTIQ &...

2024-05-14 13:40:03 ET Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer ...

2024-05-14 07:34:18 ET More on Alimera Sciences Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences Read the full article on Seeking Alpha For further details...

Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...